<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947191</url>
  </required_header>
  <id_info>
    <org_study_id>CAS-XDA-NSP/IGDB</org_study_id>
    <nct_id>NCT02947191</nct_id>
  </id_info>
  <brief_title>Collagen Membrane Combined With HUC-MSCs Transplantation in Patients With Nasal Septum Perforation</brief_title>
  <official_title>The Safety and Efficacy Assessment of Collagen Membrane Combined With Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Patients With Nasal Septum Perforation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of collagen membrane combined&#xD;
      with human clinical grade umbilical cord mesenchymal stem cells(HUC-MSCs) transplantation in&#xD;
      patients with chronic nasal septum perforation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of integrity of nasal septum assessed by endoscopic examination</measure>
    <time_frame>baseline, 1,2,3,4,8,12 weeks after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of nasal mucosal physiology assessed by olfactory test</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nasal mucosal physiology assessed by nasal mucociliary clearance time (MCT)</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nasal airway resistance assessed by rhinomanometry</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nasal obstruction assessed by acoustic rhinometry</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nasal obstructive symptom assessed by visual analogue scale (VAS)</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of nasal symptom severity assessed by total nasal symptom score (TNSS)</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in computed tomography (CT)</measure>
    <time_frame>baseline, 12 weeks after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Nasal Septum Perforation</condition>
  <arm_group>
    <arm_group_label>Collagen membrane + HUC-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collagen membrane + HUC-MSCs</intervention_name>
    <description>After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.</description>
    <arm_group_label>Collagen membrane + HUC-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with nasal septum perforation area less than 1cmÂ², and requires&#xD;
             minimally-invasive treatment.&#xD;
&#xD;
          2. Male or female, 18-45 years old.&#xD;
&#xD;
          3. Ability and willingness to regular visit to hospital and follow up during the protocol&#xD;
             Procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cystic fibrosis, immotile cilia syndrome and other genetic diseases.&#xD;
&#xD;
          2. Syphilis, leprosy, tuberculosis and other specific infections.&#xD;
&#xD;
          3. Severe Sinusitis.&#xD;
&#xD;
          4. Autoimmune diseases or long term treatment with corticosteroids.&#xD;
&#xD;
          5. Alzheimer's disease.&#xD;
&#xD;
          6. Systemic diseases (e.g.,hypertension, diabetes and so on).&#xD;
&#xD;
          7. Previous history of nasal cancer or after receiving radiotherapy.&#xD;
&#xD;
          8. Drug abuse.&#xD;
&#xD;
          9. History of mental illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwu Dai, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jianwu Dai</investigator_full_name>
    <investigator_title>Principal Investigator of Regenerative Medicine Laboratory, Institute of Genetics and Developmental Biology, CAS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Septal Perforation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

